Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Payables (2019 - 2025)

Burning Rock Biotech has reported Payables over the past 7 years, most recently at $5.8 million for Q4 2025.

  • For Q4 2025, Payables rose 21.91% year-over-year to $5.8 million; the TTM value through Dec 2025 reached $5.8 million, up 21.91%, while the annual FY2025 figure was $5.8 million, 23.9% up from the prior year.
  • Payables for Q4 2025 was $5.8 million at Burning Rock Biotech, up from $4.8 million in the prior quarter.
  • Over five years, Payables peaked at $15.6 million in Q1 2022 and troughed at $2.7 million in Q4 2023.
  • A 5-year average of $6.2 million and a median of $4.9 million in 2025 define the central range for Payables.
  • Biggest five-year swings in Payables: skyrocketed 98.36% in 2022 and later plummeted 76.74% in 2023.
  • Year by year, Payables stood at $10.2 million in 2021, then decreased by 27.55% to $7.4 million in 2022, then plummeted by 63.94% to $2.7 million in 2023, then skyrocketed by 78.73% to $4.8 million in 2024, then increased by 21.91% to $5.8 million in 2025.
  • Business Quant data shows Payables for BNR at $5.8 million in Q4 2025, $4.8 million in Q3 2025, and $4.5 million in Q2 2025.